RxDoctor Payments Data

Colleen Knoop

Nurse Practitioner · Covington, LANPI 1497862841

Payments from drug & device makers

$1,019in general payments, 2019–2025

Across 36 payments — averaging $28.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$538
  • Acadia Pharmaceuticals Inc$122
  • Boston Scientific$112
  • MDD US Operations, LLC$99
  • AbbVie$57
  • Neurocrine Biosciences, Inc.$49
  • plus $42 from 2 others

What the payments were for

  • Food & beverage$97496%
  • Education$454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,019 in reported general payments places this provider in the 70th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$33,322
Medicare patients
149
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$115,797
RytaryCarbidopa/Levodopa37$58,715
NeuproRotigotine21$29,196
Carbidopa-LevodopaCarbidopa/Levodopa446$13,395
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone35$8,761
Rasagiline Mesylate24$6,149
Carbidopa-Levodopa ErCarbidopa/Levodopa156$4,869
AmantadineAmantadine Hcl97$2,901
RivastigmineRivastigmine Tartrate46$2,662
Primidone52$1,960
Memantine Hcl48$1,359
Ropinirole Hcl39$1,303
Quetiapine Fumarate84$1,046
Gabapentin64$937
Donepezil Hcl62$690

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$49$115,79713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →